News on protein analysis, clinical proteomics, biomarkers in genetics, genomics, and molecular diagnostics.
While proteogenomic technology is still in its early stages, it will likely make its way into the clinic over the next five to 10 years, said an FDA official.
The test, which measures the kinetics of amyloid beta isoforms in blood, could enable more efficient screening of patients for Alzheimer's drug trials.
The agencies said they're aiming to "accelerate the development of proteogenomic technologies and biomarkers, as it relates to precision medicine in cancer."
While actual clinical implementation remains distant, MALDI imaging technology has advanced to the point where it might feasibly be applied to pathology.
The company expects the deal will help it launch an immunostaining technology, expand into US pharma services, and establish itself as a genetic testing leader in Japan.
Gene drives might run into biological resistance, the Economist reports.
Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.
Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.
In Science this week: full CRISPR locus integration complex structure, and more.